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Fibrate prevents cisplatin-induced proximal tubule cell death.
Background. In previous studies we have shown that cisplatin
inhibits peroxisome proliferator-activated receptor-a (PPAR-
a) activity and consequently fatty acid oxidation, and these
events precede proximal tubule cell death. In addition the use
of fibrate class of PPAR-a ligands ameliorate renal function by
preventing both inhibition of fatty acid oxidation and proximal
tubule cell death.
Methods. LLC-PK1 cells were treated with cisplatin and
apoptosis was established by the presence of nuclear fragmen-
tation and by cell cycle analysis. Proximal tubular cells treated
with cisplatin and bezafibrate were subjected to sub cellular
fractionation and the presence of Bax, Bcl-2, cytochrome c, and
active caspase-3 in the cytosolic and mitochondrial membrane
fractions was determined by Western blot analysis. PPAR-a
activity was measured by determining luciferase activity after
transfection of LLC-PK1 cells with TK-Luc 3× PPAR response
elements (PPRE), and the accumulation of nonesterified free
fatty acids was measured in lysates obtained from cells treated
with cisplatin and bezafibrate.
Results. Incubation of LLC-PK1 cells with 25 lmol/L cis-
platin for 18 hours induced 41.5% apoptosis measured by
cell cycle analysis. Cisplatin-induced apoptosis was significantly
suppressed by bezafibrate, a fibrate class of PPAR-a ligand.
Bezafibrate treatment of LLC-PK1 cells prevented cisplatin-
induced translocation of proapoptotic Bax from the cytosol
to the mitochondrial fraction, and increased the expression of
antiapoptotic molecule Bcl-2. Cisplatin-induced inhibition of
PPAR-a activity was accompanied by increased accumulation
of nonesterified free fatty acids. Pretreatment with bezafibrate
prevented both the inhibition of PPAR-a activity and the accu-
mulation of nonesterified free fatty acids induced by cisplatin.
Finally, bezafibrate prevented cisplatin-induced release of cy-
tochrome c from the mitochondria to the cytosol, and the cleav-
age of procaspase-3 to active caspase-3.
Conclusion. Bezafibrate treatment inhibits cisplatin-
mediated tubular injury by preventing the activation of various
cellular mechanisms that lead to proximal tubule cell death.
These findings support our previous observations where the use
of fibrates represents a novel strategy to ameliorate proximal
tubule cell death in cisplatin-induced acute renal failure.
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Fibric acid derivatives (fibrates) have been used in clin-
ical practice for more than two decades as a class of agents
known to decrease triglyceride levels while substantially
increasing high-density lipoprotein (HDL) cholesterol
levels, with a limited but significant additional lowering
effect on low-density lipoprotein (LDL) cholesterol lev-
els. Their hypolipidemic effects can be explained by their
specific binding to and activation of nuclear receptor per-
oxisome proliferator-activated receptor-a (PPAR-a) [1].
Previous work from our laboratory has established that
the use of fibrates protects renal function primarily by
increasing renal fatty acid oxidation as well as prevent-
ing proximal tubule cell death in the animal models of
ischemia/reperfusion (I/R) and cisplatin-induced acute
renal failure [2–4]. PPAR-a is a transcription factor ex-
pressed in the renal proximal tubule which upon ligand
activation, heterodimerizes with the retinoic X receptor
(RXR) and regulates gene transcription by binding to
PPAR response elements (PPRE) located in the regula-
tory regions of target genes involved in lipid metabolism
[5–7]. Our most recent work also suggests that the admin-
istration of fibrates ameliorates cisplatin-induced acute
renal failure by preventing proximal tubule cell apop-
tosis and necrosis [8]. Although the beneficial effect of
fibrates on decreasing extracellular lipid levels has been
well established, the intracellular mechanism(s) by which
fibrates prevent proximal tubule cell death in cisplatin
mediated nephrotoxicity have not been previously ex-
amined in renal proximal tubular cells in culture.
Cisplatin is an effective chemotherapeutic agent used
in the treatment of a wide variety of cancer malignan-
cies [9–11]. Proximal tubular damage by cisplatin leads
to acute renal failure and high mortality [12]. Previous
studies have examined the cellular mechanisms by which
cisplatin causes proximal tubular cell death [13, 14]. Low
concentrations result in apoptotic cell death, while high
concentrations (more than 100 lmol/L) produce necrosis
[15]. Caspase activation initiated by death receptors has
been demonstrated in vivo and in vitro models of cisplatin
nephrotoxicity [16–19]. Several studies suggest that Bax
translocation from the cytosol to the mitochondria and
subsequent release of cytochrome c represent an impor-
tant mechanism involved in cisplatin-induced apoptotic
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cell death [20, 21]. In addition, recent work has described
the involvement of endoplasmic reticulum stress with
activation of caspase 12 [22], as well as p53 phospho-
rylation and increased transcriptional activity [23], and
p53-mediated transactivation of caspases [24] as addi-
tional cellular mechanisms by which cisplatin mediates
tubular cell apoptosis.
In the present study we have examined the cellu-
lar mechanisms by which bezafibrate prevents cisplatin-
induced proximal tubule cell death. Our studies suggest
that bezafibrate suppresses apoptosis by preventing cis-
platin induced translocation of proapoptotic Bax from
the cytosol to the mitochondria, and also by increasing
the expression of mitochondrial Bcl-2. Bezafibrate also
prevented cisplatin-induced cytochrome c release from
the mitochondrial to the cytosolic compartment, and sig-
nificantly reduced cisplatin-induced caspase 3 activation.
In addition, bezafibrate prevented cisplatin-induced in-
hibition of PPAR-a activity and this effect was accom-
panied by reduced intracellular accumulation of neutral
lipids and nonesterified free fatty acids. Altogether these
findings lend support to our previous observations where
the use of PPAR-a ligands like fibrates ameliorated renal
function by increasing fatty acid oxidation and preventing
proximal tubule cell death.
METHODS
LLC-PK1 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). Cells were
maintained in medium 199 supplemented with 5% fe-
tal bovine serum (FBS), 1% antibiotic and antimycotic
(Gibco-BRL, Bethesda, MD, USA). Bezafibrate and all
other chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Bcl-2 and Bax antibodies
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Cytochrome c antibody was obtained
from Upstate Biotechnology (Lake Placid, NY, USA).
Caspase-3 antibody was obtained from Cell Signaling
Technology (Beverly, MA, USA). b-actin antibody was
from Chemicon (Temecula, CA, USA), cytochrome c ox-
idase IV subunit antibody was obtained from Molecu-
lar Probes (Eugene, OR, USA). For the majority of the
experiments using Western blot analysis LLC-PK1 cells
were grown in 75 cm2 flasks and incubated in the absence
or presence of 100 lmol/L bezafibrate for 72 hours and
then treated with 25 lmol/L cisplatin for another 18 hours.
Apoptotic assays: 4′, 6-diamino-2-phenylindole (DAPI)
staining for nuclear fragmentation
Cells were seeded on cover slips in a 6-well plate and
were grown as mentioned in the Methods section above.
Cells were rinsed two times with phosphate-buffered
saline (PBS) and fixed in 10% formalin in neutral buffer
for 2 minutes. Cells were then rinsed with PBS two times
following fixation. The nuclear staining was performed
using mounting medium with DAPI (Vector Laborato-
ries Inc., Burlingame, CA, USA). The slides were then
examined using a digital camera (model) attached to the
Olympus BH-2 microscope.
Cell cycle analysis and quantitation of apoptosis
LLC-PK1 cells were collected after trypsinization and
then fixed in 70% ethanol. After RNase treatment cells
were incubated with 5 lg/mL propidium iodide and an-
alyzed with a fluorescence-activated cell sorter (FACS)
calibur analyzer (Becton Dickinson, Franklin Lakes, NJ,
USA). The cell cycle distribution was determined using
the CellQuest software. Cells in the sub-G1 phase were
considered apoptotic.
PPAR-a activity
PPAR-a transcriptional activity was measured as previ-
ously described [25] using the pTK-(ACO3)-Luc reporter
construct containing three copies of the of the rat acetyl
coenzyme A (acetyl-CoA) oxidase promoter PPRE un-
der the control of the herpes virus thymidine kinase pro-
moter linked to the luciferase reporter gene. LLC-PK1
cells grown in 6-well plates were transiently transfected
with 4 lg of reporter construct and 0.5 lg of RSV-b-
galactosidase (b-gal) plasmid as an internal control using
the Lipofectamine reagent (Invitrogen, Carlsbad, CA,
USA) for 6 hours under serum-free conditions. After
6 hours, medium was replaced with medium 199 supple-
mented with 5% FBS and the cells were incubated with
bezafibrate or vehicle for additional 48 hours and then
followed by 18 hours of incubation with cisplatin. Lu-
ciferase activity of cell lysates was then determined using
a luciferase assay system (Promega, Madison, WI, USA)
as previously described [25]. Transfection efficiency was
normalized to (b-gal activity and expressed as fold induc-
tion of vehicle-treated control cells. Values are means ±
SE of three separate experiments.
Oil red O staining for neutral lipids
Accumulation of intracellular lipids was first qualita-
tively assessed using an Oil Red O stain as an indicator
of neutral lipid accumulation. The cells were seeded in
6-well plates and prior to staining were rinsed twice with
PBS, and then fixed in 10% formalin in neutral buffer for
15 minutes. The cell monolayers were then washed twice
with water and incubated with 2% (wt/vol) Oil Red O
reagent for 30 minutes. Excess stain was removed from
the monolayers by washing at least four times with dis-
tilled water and cell morphology was determined by tak-
ing digital images through an inverted microscope (Nikon
Eclipse 200) equipped with a Hoffman Modulation Con-
trast Optics (Melville, NY, USA).
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Free fatty acid measurement
After experimental conditions LLC-PK1 cells were
harvested from the flasks by scraping them carefully
into PBS (pH 7.4) and centrifuged at 1500g for 3 min-
utes. Cell pellets were homogenized using a dounce
homogenizer with 50 strokes, then briefly sonicated in
PBS (pH 7.4) and centrifuged at 1000g for 10 min-
utes. Supernatants were collected and free fatty acids
were measured using Wako NEFA-C Test Kit (Wako
Chemicals USA, Inc., Richmond, VA, USA). In this as-
say nonesterified free fatty acids present in cell lysates
are treated with acetyl-CoA synthetase (ACS) in the
presence of adenosine triphosphate (ATP), magnesium
cations, and CoA to form the thiol esters of CoA, acetyl-
CoA, as well as the byproducts adenosine monophos-
phate (AMP) and pyrophosphate (PR). The acetyl-CoA
produced is then oxidized by adding acetyl-CoA ox-
idase (ACOD) to produce hydrogen peroxide which
in the presence of added peroxidase (POD) allows
the oxidative condensation of 3-methyl-N-ethyl-N-(b-
hydroxyethyl-aniline(MEHA) with 4-aminoantipyrine
to form a purple-colored adduct with an absorption max-
imum at 550 nm. Hence, the amount of nonesterified free
fatty acids is determined from the optical density mea-
sured at 550 nm.
Immunofluorescence localization of Bax
Cells grown on sterile glass coverslips were treated with
100 lmol/L bezafibrate for 72 hours followed by 18 hours
of cisplatin treatment. After these treatments, the cells
were washed in PBS and fixed in 2% parformaldehyde
in PBS for 15 minutes. Cells were washed twice in PBS,
and then they were permeabilized for 1 hour in blocking
buffer containing 1% bovine serum albumin (BSA), 1%
goat serum, 0.1% saponin, 1 mmol/L CaCl2, 1 mmol/L
MgCl2, and 2 mmol/L NaV2O5 in PBS. Cells were then in-
cubated with 1:200 rabbit anti-Bax antibody for 1 hour in
a humidified incubator kept at 37◦C. After three washes in
buffer containing 1% BSA and 0.1% saponin in PBS, cells
were incubated at 37◦C for 1 hour with 1:500 of Alexa-
fluor–conjugated secondary antibody (goat antirabbit) in
blocking solution and again washed with washing buffer.
The nuclei were stained with 0.5 lg/mL DAPI for 5 min-
utes, and then the cells were washed twice in washing
buffer. Coverslips were then mounted on slides using
antifade mounting media (Molecular Probes) and Bax
immunolocalization was examined using a Zeiss decon-
voluted fluorescent microscope (Zeiss, Thornwood, NY,
USA).
Cytochrome C release
LLC-PK1 cells were harvested from the flasks by gen-
tle scraping into PBS and centrifuged at 1500g for 3 min-
utes. Cell pellets were then resuspended in PBS and cen-
trifuged at 850g for 2 minutes in Eppendorf tubes. From
these cell pellets, mitochondria and cytosolic fractions
were isolated using a Pierce Kit (Pierce, Rockford, IL,
USA), according to manufacturer’s instructions. A total
of 20 lg of protein obtained from mitochondria and cy-
tosolic fractions were separated on a 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotted on to a nitrocellulose membrane and
probed with a cyctochrome c antibody (1:1000). Proteins
were visualized using enzyme-linked enhanced chemilu-
minescence (ECL) (Amersham, Arlington Heights, IL,
USA). The membranes were stripped and then probed
with cyclooxygenase (COX) IV antibodies for mito-
chondrial fractions and b-actin antibodies for cytosolic
fractions as internal controls. Signals on the blots were
visualized by autoradiography and quantitated by densit-
ometry using ImageQuant image analysis system (Storm
Optical Scanner) (Molecular Dynamics, Sunnyvale, CA,
USA).
Caspase-3 activation
Caspase-3 activity was estimated by immunoblot anal-
ysis showing the appearance of active caspase-3 pro-
tein band of 17 kD size from the procaspase-3 band of
32 kD size. Cells were harvested [50 mmol/L Tris, pH
7.4, 100 mmol/L NaCl, 2.5 mmol/L ethylenediaminete-
traacetic acid (EDTA), 1% Triton X-100, 0.5% NP-40,
2.5 mmol/L Na3VO4, 1 mmol/L phenylmethylsulfonyl
fluoride (PMSF), 25 lg/mL aprotinin and leupeptin, and
50 lg/mL soybean trypsin inhibitor]. The cells were in-
cubated on ice for 10 minutes and sonicated briefly for
10 seconds. Cell homogenates were subsequently cen-
trifuged at 11,000g for 15 minutes at 4◦C, and the su-
pernatant collected. Protein concentration was measured
using the protein assay kit from Bio-Rad Laboratories
(Hercules, CA, USA). Supernatants containing 50 lg of
protein were separated on a 12% SDS-PAGE and then
electroblotted to a nitrocellulose membrane. The mem-
brane was blocked overnight with 5% nonfat dried milk
in TBST buffer (20 mmol/L Tris, pH 7.6, 100 mmol/L
NaCl, and 0.1% Tween 20), followed by 3 hours of in-
cubation with the primary antibody (1:1000 dilution)
in TBST buffer containing 5% nonfat dried milk at
room temperature. After washing three times with TBST
buffer, the membranes were incubated with a horseradish
peroxidase–conjugated goat antirabbit IgG as a second
antibody (1:5000 dilution) for 1 hour at room temper-
ature. Proteins were visualized using by enzyme-linked
ECL (Amersham). The membranes were stripped and
then probed with b-actin antibodies (Chemicon) as an
internal control. Signals on the blots were visualized by
autoradiography and quantitated by densitometry using
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ImageQuant image analysis system (Storm Optical Scan-
ner) (Molecular Dynamics).
Statistics analysis
Results are presented as means ± SE. Statistical anal-
ysis was performed using unpaired Student t tests. A
P value of < 0.05 was considered to be statistically
significant.
RESULTS
Bezafibrate prevents cisplatin-induced apoptotic
cell death
We studied four experimental groups: (1) control group
represents LLC-PK1 cells incubated for 90 hours with
vehicle [0.1% dimethyl sulfoxide (DMSO)]; (2) cisplatin
group represents cells incubated for 72 hours with vehi-
cle followed by additional incubation for 18 hours with
25 lmol/L cisplatin; (3) bezafibrate group represents cells
incubated for 72 hours in the presence of 100 lmol/L
bezafibrate and then incubated for additional 18 hours
in regular media; and (4) bezafibrate + cisplatin group
represents cells incubated for 72 hours with 100 lmol/L
bezafibrate then followed by additional incubation for
18 hours with cisplatin 25 lmol/L. Qualitative estimation
of apoptotic cell death was obtained by DAPI staining
which demonstrated nuclear condensation and fragmen-
tation. In addition estimation of apoptotic cells was also
done by FACS analysis using quantification of the sub-G1
fraction in cells stained with propidium iodide. As shown
in Figure 1A incubation for 18 hours with 25 lmol/L cis-
platin led to significant amount of nuclear condensation
and fragmentation as shown by DAPI staining when com-
pared to untreated control cells. Preincubation of LLC-
PK1 cells for 72 hours with 100 lmol/L bezafibrate per se
did not have a significant effect on cell death; however, it
significantly reduced cisplatin-induced nuclear fragmen-
tation as shown in Figure 1A. Apoptotic cell death quan-
tified by FACS analysis of propidium iodide–stained cells
(sub-G1 fraction) was increased from 3% in control un-
treated cells to 41% in cisplatin-treated cells. Preincu-
bation of LLC-PK1 cells for 72 hours with 100 lmol/L
bezafibrate significantly reduced cisplatin-induced cell
death to 13%, as shown in Figure 1B. Figure 1C sum-
marizes the results of three separate experiments.
Cisplatin induces the accumulation of neutral lipids and
nonesterified fee fatty acids
Our previous studies have shown that during renal
ischemia or hypoxic injury to freshly isolated proximal
tubular cells there is an increased accumulation of intra-
cellular fatty acids which precedes the development of
proximal tubule cell death [26]. Furthermore, we have
shown that inhibition of fatty acid oxidation in the per-
oxisomes and mitochondria represent a common patho-
genetic mechanism for long chain fatty acid accumulation
during acute renal failure in the models of I/R injury and
cisplatin-induced acute renal failure [2–4]. Therefore, in
the present study we first examined whether intracellu-
lar lipids accumulate in proximal tubule cell in culture
by performing intracellular stain of neutral lipids using
the Oil Red O dye. As shown in Figure 2B, cisplatin
caused a significant accumulation of neutral lipids de-
tected at 18 hours after cisplatin treatment when com-
pared to control-untreated cells shown in Figure 2A.
This accumulation of neutral lipids was predominantly
detected in the cytosolic fraction of LLC-PK1 cells. Pre-
treatment of LLC-PK1 cells for 72 hours with 100 lmol/L
bezafibrate alone did not have a significant effect on neu-
tral lipid staining as shown in Figure 2C, but prevented
the accumulation of neutral lipids induced by cisplatin as
shown in Figure 2D. Since neutral lipid accumulation rep-
resents the accumulation of nonesterified free fatty acids,
triglycerides, diglycerides, and cholesterol esters, we next
examined specifically the effects of cisplatin on the intra-
cellular accumulation of nonesterified free fatty acids in
proximal tubule cells in culture. As shown in Figure 2E,
cisplatin increased intracellular concentration of nones-
terified free fatty acids from control 1.02 ± 0.03 to 1.96 ±
0.12 mEq/L/mg protein after 6 hours. Further accumula-
tion was detected after 18 hours of cisplatin incubation
(2.86 ± 0.03 mEq/L/mg protein).
Bezafibrate prevents cisplatin-induced inhibition
of PPAR-a activity and accumulation of intracellular
nonesterified free fatty acids
PPAR-a activity measured as luciferase activity of
acetyl-CoA was reduced by at least 50% when LLC-PK 1
cells were incubated with 25 lmol/L cisplatin for 18 hours,
when compared to untreated control cells as shown in
Figure 3A. In contrast PPAR-a activity was significantly
increased (5.6-fold) by pretreatment for 48 hours with
bezafibrate alone, and this transcriptional activity re-
mained elevated even in the presence of cisplatin. When
bezafibrate was given for 48 hours it did prevent cisplatin-
induced caspase-3 activation by 50%, rather than 75%
which was the inhibition seen at 72 hours. We did not
see any protective effect against apoptosis or caspase-
3 activation when bezafibrate was given for 24 hours
prior to cisplatin. To measure PPAR-a transcriptional
activity we chose 48 hours of pretreatment with bezafi-
brate based on these preliminary results. To further exam-
ine the potential association between reduced PPAR-a
activity and nonesterified free fatty acid accumulation
by cisplatin, we next examined the effect of bezafibrate
and cisplatin on the intracellular levels of nonesterified
free fatty acids. As shown in Figure 3B cisplatin induced
the accumulation of nonesterified free fatty acids from
2684 Nagothu et al: Antiapoptotic effects of fibrate in LLC-PK1 cells
A Control Cisplatin Bezafibrate
Bezafibrate+ 
Cisplatin
G1-81.41% 
S-5.47% 
G2-M-6.90% 
SubG1-3.27%
G1-47.24% 
S-4.12% 
G2-M-1.60% 
SubG1-46.01%
G1-76.93% 
S-7.10% 
G2-M-7.51% 
SubG1-2.12%
G1-69.31% 
S-11.75% 
G2-M-3.38% 
SubG1-13.15%
50
45
40
35
30
25
20
15
10
5
0
%
 A
po
pt
os
is
Bezafibrate
Cisplatin
− − + +
− + − +
Ce
ll N
um
be
r
B
C
DNA DNA DNA DNA
Fig. 1. Bezafibrate prevents cisplatin-induced apoptotic cell death. We studied four experimental groups. Control group represents LLC-PK1
cells incubated for 90 hours with vehicle [0.1% dimethyl sulfoxide (DMSO)], cisplatin group represents cells incubated for 72 hours with vehicle
followed by additional incubation for 18 hours with 25 lmol/L cisplatin, Bezafibrate group represents cells incubated for 72 hours in the presence
of 100 lmol/L bezafibrate and then incubated for additional 18 hours in regular media, bezafibrate + cisplatin group represents cells incubated for
72 hours with 100 lmol/L bezafibrate then followed by additional incubation for 18 hours with cisplatin 25 lmol/L. (A) The nuclear staining with
4′, 6-diamino-2-phenylindole (DAPI) of cells treated as described in each individual group. (B) Fluorescence-activated cell sorter (FACS) analysis
of LLC-PK1 cells from the same four groups as described in (A). All cells were harvested as mentioned in the Methods section and stained with
propidium iodide before FACS analysis. Peaks representing histograms of cell numbers in G1, S, and G2. M phases and apoptotic (sub-G1) phases
are shown. (C) The percentages of sub-G1/G0 (apoptotic cells) cells. ∗P < 0.0005 compared with control; #P < 0.05 compared with cisplatin in
unpaired Student t test.
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Fig. 2. Effects of bezafibrate on cisplatin-
induced neutral lipid accumulation. LLC-PK1
cells were incubated using four different ex-
perimental conditions as described in the
Methods section. (A) Control using Oil Red
O staining. (B) Csplatin using Oil Red O
staining. (C) Beazafibrate using Oil Red O
staining. (D) Beazafibrate + cisplatin using
Oil Red O staining. Results are representa-
tive of three independent experiments. (E)
Time course of cisplatin-induced nonesteri-
fied free fatty acid accumulation. Cells were
treated with 25 lmol/L cisplatin for 0, 6, 12,
and 18 hours, respectively, and nonesterified
free fatty acids were measured as described
in the Methods section. ∗P < 0.05 compared
with control by unpaired Student t test.
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Fig. 3. Effects of cisplatin and bezafibrate on peroxisome proliferator-activated receptor-a (PPAR-a) activity. (A) After transient transfection
with pTK(ACO3)-Luc reporter and RSV-b-galactosidase (b-gal) cells were subjected to four experimental conditions control untreated, cisplatin,
bezafibrate, and bezafibrate+cisplatin group as described in the Methods section. Transfection efficiency was normalized to b-gal activity. ∗∗P <
0.005; ∗P < 0.05 compared with control group by unpaired Student t test. (B) The effects of cisplatin and bezafibrate on the accumulation of
nonesterified free fatty acid (NEFA). Cells were pretreated with bezafibrate for 72 hours and followed by 25 lmol/L cisplatin for 18 hours. ∗P <
0.05 compared with control; #P < 0.05 compared with cisplatin group by unpaired Student t test.
1.02 ± 0.03 mEq/L/mg protein in untreated cells to 2.86 ±
0.03 mEq/L/mg protein after 18 hours of treatment, and
this effect was blunted in the presence of bezafibrate.
These results allow us to conclude that the cytoprotective
effects of bezafibrate relate not only to increased PPAR-a
activity but also to the inhibition of intracellular accumu-
lation of nonesterified free fatty acids, which occurs as a
result of increased intracellular fatty acid oxidation.
Bezafibrate prevents the cisplatin-induced translocation
of Bax
Activation and translocation of Bax to mitochondria
precedes the cytochrome c release into the cytosol [20,
21]. Hence, we examined the time course of Bax translo-
cation from cytosol into mitochondria after cisplatin
treatment. As shown in Figure 4A, Western blot analysis
demonstrates the accumulation of a small yet significant
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Fig. 4. Time course of cisplatin-induced translocation of Bax from cytosol to the mitochondria: LLC-PK1 cells were treated with 25 lmol/L
cisplatin for 0, 3, 6, 12, and 18 hours, respectively, and then subjected to subcellular fractionation and Western blot analysis using a Bax antibody
as described in the Methods section. (A) The mitochondrial fractions. (B) The cytosolic fractions. Antibodies against cycloxygenase (COX) IV
and b-actin were used as loading controls for each subcellular fraction. (C) and (D) A summary of the results of three separate experiments. Bars
correspond to normalized immunoreactive Bax (mitochondrial Bax was normalized using COX IV and cytosolic Bax was normalized with b-actin
proteins, respectively). ∗P < 0.05 compared with control (0 hours) group by unpaired Student t test. (E) Immunoblot analysis of mitochondrial
and cytosolic fractions using Bax and Bcl-2 antibodies. Cells were subjected to four experimental conditions as described in the Methods section.
Control untreated cells, cisplatin, bezafibrate, and bezafibrate + cisplatin–treated cells. (F) and (G) A summary of the results of three separate
experiments. Bars correspond to normalized immunoreactive Bax and Bcl-2 (mitochondrial Bax and Bcl-2 were normalized using COX IV and
cytosolic Bax and Bcl-2 were normalized with b-actin proteins, respectively). ∗P < 0.05; #P < 0.05 compared with control group; †P < 0.05 compared
with group by unpaired Student t test.
amount of Bax protein in the mitochondrial fraction be-
ginning at 6 hours and gradually increasing up to 18 hours
of cisplatin incubation. The results from three separate
experiments showed that cisplatin-induced Bax translo-
cation from cytosolic to mitochondrial membrane com-
partment occurs between 6 and 12 hours as now shown in
Figure 4A through D. Concomitantly, a profound reduc-
tion in the protein levels of cytosolic Bax were seen after
12 hours of cisplatin incubation as shown in Figure 4B.
Treatment with 100 lmol/L bezafibrate for 72 hours
did not have a significant effect in the cellular distribu-
tion of Bax, however, did prevent cisplatin-induced Bax
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Fig. 4. (continued)
translocation from the cytosol to the mitochondrial frac-
tion as shown in Figure 4E. Since recent reports sug-
gest that over expression of Bcl-2 in rat proximal tubular
cells in culture can prevent cisplatin-induced apoptosis,
we next examined the effect of cisplatin and bezafibrate
on the protein levels of Bcl-2 protein. As shown also in
Figure 4E, cisplatin did not affect the mitochondrial pro-
tein levels of Bcl-2 when compared to untreated cells. Pre-
treatment of LLC-PK1 cells with bezafibrate increased
the expression of mitochondrial Bcl-2 protein, and this
increased expression of Bcl-2 was not altered by the ad-
dition of cisplatin. The results of three separate experi-
ments in which cytosolic and mitochondrial distribution
of Bax and Bcl-2 were measured by Western blot analysis
are summarized in Figure 4F and G.
To further confirm changes in the cellular distribution
of intracellular Bax caused by cisplatin, we next per-
formed immunostaining studies using a specific anti-Bax
antibody. As shown in Figure 5A, a diffuse red staining
pattern was seen in the cytosolic compartment of un-
treated LLC-PK1 cells. Cisplatin treatment for 18 hours
induced translocation of Bax, which was seen as a punc-
tate mitochondrial pattern of intense red fluorescence
as seen in Figure 5B. Pretreatment of cells with bezafi-
brate reduced the punctate mitochondrial pattern in-
duced by cisplatin as seen in Figure 5D. Immunostaining
of cisplatin-treated cells using a fluorescence antibody to
cytochrome c oxidase IV demonstrated colocalization of
this mitochondrial protein staining with the cellular stain
observed for Bax in cisplatin-treated cells. These results
further corroborate the results of Western blot analysis,
and suggest that the cellular localization of cisplatin-
treated cells corresponded to the mitochondrial compart-
ment as shown in Figure 5E and F.
Effect of bezafibrate on cisplatin-induced mitochondrial
release of cytochrome c
The above results suggest that bezafibrate prevents the
activation of an intrinsic mitochondrial pathway of apop-
totic cell death. Therefore, we next determined whether
bezafibrate affected the distribution of cytochrome c in
cisplatin-treated cells. Subcellular fractionation followed
by Western blot analysis showed that in the presence
of cisplatin cytochrome c was released from the mito-
chondria into the cytosol in a time-dependent fashion
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Fig. 5. Effects of cisplatin and bezafibrate on
immunofluorescent localization of Bax. Cells
were pretreated with either vehicle (control)
or bezafibrate for 72 hours and followed by
25 lmol/L cisplatin for 18 hours. (A) Control.
(B) Cisplatin. (C) Bezafibrate. (D) Beazafi-
brate + cisplatin. Immunofluorescence mi-
croscopy was carried out as mentioned in
the Methods section. Cisplatin-treated cells
showed punctate mitochondrial pattern with
intense red staining. Instead no punctate mi-
tochondrial pattern was observed in the cells
pretreated with bezafibrate. Results are rep-
resentative of three independent experiments.
(E) A typical immunostaining of cisplatin-
treated cells using a cyclooxygenase (COX)
IV antibody as a mitochondrial marker. (F)
Cells immunostained with a Bax antibody
demonstrating colocalization of the Bax im-
munofluorescence signal with the mitochon-
drial compartment.
with appreciable amounts detected in the cytosolic frac-
tion between 6 and 9 hours of cisplatin incubation as
shown in Figure 6A and B. Bezafibrate alone did not af-
fect the cellular distribution of cytochrome c, but signifi-
cantly prevented cisplatin-induced cytochrome c release
into the cytosolic compartment, as shown in Figure 6C
and D. Analysis of three separate experiments, as shown
in Figure 6E, further confirmed the observations that
cisplatin induced the release of cytochrome c from the
mitochondrial into the cytosolic compartment and that
bezafibrate prevented this release of cytochrome. There-
fore, these results allow us to conclude that bezafibrate
likely exerts a cytoprotective effect by preventing the re-
lease of apoptogenic factors such as cytochrome c.
Effect of bezafibrate on cisplatin-induced caspase-3
activation
Our experiments showed that bezafibrate significantly
ameliorated apoptosis. We wondered whether bezafi-
brate could inhibit cisplatin-induced caspase-3 activa-
tion which has been reported in previous studies [19].
Figure 7A shows that cisplatin induced a time-dependent
increase in the activation of caspase-3 reflected as the in-
creased cleavage of procaspase-3 (32 kD protein band)
to active caspase-3 which was detected as the presence of
a new 17 kD protein band, predominantly after 12 hours
of incubation. Figure 7B represents the time-dependent
fold increase in the activation of caspase-3. Bezafibrate
alone did not have any effect on the activation of caspase-
3. However, cisplatin-induced activation of caspase-3 was
significantly inhibited (75%) by bezafibrate treatment for
72 hours as shown in Figure 7C. Analysis of three sepa-
rate experiments, as shown in Figure 7D, further con-
firmed the observations that cisplatin-induced activation
of caspase-3 was prevented by bezafibrate.
DISCUSSION
The present study extends our previous observations
demonstrating the beneficial effects of fibrates on cyto-
protection in the model of cisplatin-induced acute renal
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Fig. 6. Time course of cisplatin-induced cy-
tochrome c release. (A) The immunoblot anal-
ysis of cytosolic fractions of cells treated with
25 lmol/L ciplatin for 1, 3, 6, 9, and 12 hours.
(B) The immunoblot analysis of mitochon-
drial fractions of cells treated with cisplatin.
b-actin antibody was used as an internal con-
trol for cytosolic fractions and cyclooxygenase
(COX) IV antibody was used as an internal
control of the mitochondrial fractions. Results
are representative of three independent ex-
periments. (C) The immunoblot analysis of
cytosolic fractions. (D) The immunoblot anal-
ysis of mitochondrial fractions of cells incu-
bated under the four different experimental
conditions described in the Methods section.
b-actin antibody was used as an internal con-
trol for cytosolic fractions and COX IV an-
tibody was used as an internal control of the
mitochondrial fractions. (E) The values corre-
sponding to normalized cytochrome c protein
levels. ∗P < 0.005; #P < 0.05 compared with
control group by unpaired Student t test.
failure. In order to exclude the possibility that pretreat-
ment with fibrates for 72 hours alters the cellular uptake
or efflux of cisplatin, we measured cisplatin content in
cells treated with bezafibrate and found no differences
in the uptake of cisplatin when cells are pretreated with
bezafibrate. The study presented here in proximal tubular
cells in culture demonstrate a time-dependent sequence
of intracellular events by which cisplatin leads to proxi-
mal tubule cell death. Within the first 6 to 12 hours af-
ter cisplatin exposure we detected the translocation of
cytosolic Bax to the mitochondria. In addition, accumu-
lation of nonesterified free fatty acids, likely as a result
of reduced intracellular PPAR-a activity, was detected
as early as 6 hours of cisplatin administration, suggesting
that these two cellular events precede the development
of mitochondrial permeabilization. Then at 6 to 9 hours
of cisplatin incubation, our studies documented the re-
lease of cytochrome c into the cytosol. These intracel-
lular events were then followed by caspase-3 activation,
detected at 12 hours, and the development of apoptotic
cell death seen after 18 hours of cisplatin incubation man-
ifested as increased nuclear fragmentation.
A recent study has examined the role of various cel-
lular pathways leading to tubular cell apoptosis in rat
proximal tubular cells in culture exposed to cisplatin
[23]. The authors demonstrated the early presence of p53
phosphorylation having an important role in cisplatin-
mediated proximal tubule cell death. Those investigators
also found that although caspase inhibitors, and increased
Bcl-2 expression ameliorated cisplatin-induced apopto-
sis, those two therapeutic maneuvers did not inhibit p53
phosphorylation. Since the use of dominant-negative p53
abolished apoptosis the authors concluded that p53 phos-
phorylation and induction of gene transcription likely
plays an important role in proximal tubule cell death. Our
present study did not address the role of p53 in cisplatin-
induced proximal tubular cell death; however, the early
effects of cisplatin injury suggest that Bax translocation
could occur independently of p53 increased transcrip-
tional activity as recently demonstrated by other investi-
gators [27].
Mitochondria plays an essential role in cisplatin-
induced apoptosis [28]. Death signals transduced to
mitochondria cause mitochondria outer membrane per-
meabilization resulting in the release of mitochon-
drial proteins such as cytochrome c, Smac/Diablo, AIF,
Omi/HtrA2, and Endo G into the cytosol or nucleus
where they are actively involved in the process of cas-
pase activation and protein/DNA degradation [29]. The
Bcl-2 family of proteins which consists of both anti- and
proapoptotic molecules controls the mitochondrial func-
tion in apoptosis [30]. The antiapoptotic Bcl-2 family
proteins such as Bcl-2 and Bcl-XL prevent the release
of apoptogenic molecules from mitochondria. In con-
trast, proapoptotic Bcl-2 family proteins, including the
Bax and the BH3 subfamilies, are death effectors abso-
lutely required for the mitochondrial pathway of apop-
tosis [31, 32]. In healthy cells, Bax exists in an inactive
form mainly in the cytosol, but can be induced to undergo
a conformational change and migrate to the mitochon-
dria by apoptotic signals [33, 34]. The conformationally
changed Bax protein oligomerizes on the mitochondrial
outer membrane and induces cytochrome c release [35].
The antiapoptotic Bcl-2 family proteins prevent Bax con-
formational change and when overexpressed can prevent
apoptosis [36]. Recent studies have examined the poten-
tial mechanisms by which Bax could be activated and in
turn initiate apoptotic cell death. Bax can interact with a
regulatory protein [37], Bax can be translocated to mito-
chondria as a result of changes in intracellular pH [38],
and, finally, Bax can be also activated and translocated in
response to increased expression of Bid [39].
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Fig. 7. Effect f of cisplatin and bezafibrate
on caspase-3 activation. (A) The time course
of cisplatin-induced capspase-3 activation de-
termined my immunoblot analysis. LLC-PK1
cells were treated with 25 lmol/L cisplatin for
0, 8, 10, 12, and 14 hours. Results are rep-
resentative of two independent experiments.
(B) The amount of active caspase-3 measured
by densitometry. (C) A representative autora-
diogram of immunoblot analysis of cell lysates
obtained from four experimental conditions
and a caspase-3 antibody as described in the
Methods section. (D) The quantification of
active caspase-3 normalized by b-actin. #P <
0.005 compared with cisplatin only group by
unpaired Student t test.
Our studies here corroborate previous observations
where we demonstrated the inhibition of PPAR-a activ-
ity as early as 6 hours after exposure to cisplatin. We
also showed in those earlier studies that cisplatin deacti-
vated PPAR-a by reducing its DNA binding activity, and
the availability of its tissue dependent coactivator PGC-
1 [25]. We document for the first time here in proximal
tubule cells in culture the intracellular accumulation of
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neutral lipids, and in particular the accumulation of in-
tracellular nonesterified free fatty acids which represents
an additional cellular mechanism, along with the translo-
cation of cytosolic Bax to the mitochondria, by which
cisplatin induces proximal tubule cell death. Although
our studies cannot conclusively establish a direct cause-
effect of fatty acid accumulation and the development of
apoptosis, recent studies have shown that the lipotoxic
effect of saturated fatty acids such as palmitate occur as a
result of direct interaction of the fatty acid with adenine
nucleotide translocase leading to uncoupled respiration
[40], and opening of the mitochondrial permeability tran-
sition pore in a ceramide- independent fashion [41].
Bezafibrate prevents cisplatin-induced proximal tubule
cell death
Our findings showing an increased accumulation of
cellular neutral lipids and more specifically nonesteri-
fied free fatty acids in cisplatin-treated proximal tubule
cells in culture support the pathogenetic role of lipotox-
icity as a potential cause of mitochondrial injury leading
to apoptotic cell death. Furthermore, the demonstration
that bezafibrate treatment prevents the accumulation of
nonesterified free fatty acids induced by cisplatin and re-
duces proximal tubule cell death lends further support
to this hypothesis. A recent study by Zager, Johnson, and
Hanson [42] has confirmed our findings of increased lipo-
toxicity during acute renal failure. Using various animal
models of renal injury such as I/R, lipopolysaccharide
(LPS), and glycerol-induced rhabdomyolysis, those in-
vestigators found increased levels of triglycerides in renal
cortex and in the proximal tubule. Since fibrate treatment
also reduces triglyceride levels in addition to decreasing
nonesterified free fatty acid levels [1], it is quite possi-
ble this mechanism also contributes to the observed re-
duced apoptotic cell death in cisplatin-treated proximal
tubules. Other studies in liver tissue have shown that the
administration of PPAR-a ligands like fibrates leads to
the activation of PPAR-a, and results in a pleiotropic
response that includes increased peroxisome prolifera-
tion, up-regulation of fatty acid oxidation, reduced in-
flammation, and suppression of apoptosis [43–45]. Our
most recent in vivo studies in mice exposed to cisplatin
and fibrates suggest also that in kidney tissue PPAR-a
ligands ameliorate acite renal failure by having both anti-
apoptotic [8] and anti-inflammatory effects (unpublished
observations).
CONCLUSION
Our present study in proximal tubule cells in cul-
ture offer several mechanisms that could explain why
bezafibrate prevents cisplatin-induced proximal tubule
cell death. Bezafibrate prevented apoptotic cell death at
various levels: (1) bezafibrate prevented Bax activation
and translocation from the cytosolic to the mitochondrial
compartment; (2) bezafibrate increased the expression of
antiapoptotic Bcl-2 similarly to what has been described
in liver tissue [46]; (3) bezafibrate prevented the inhibi-
tion of PPAR-a activity and the accumulation of non-
esterified free fatty acids; (4) bezafibrate prevented the
release of cytochrome c from the mitochondria to the
cytosolic compartment; and (5) bezafibrate ameliorated
cisplatin-induced caspase-3 activation. Altogether these
intracellular events resulted in amelioration of apoptotic
cell death.
Further studies will be needed to clarify additional
mechanisms by which improved substrate utilization pre-
vents apoptotic cell death in cisplatin-treated proximal
tubules.
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